Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin with Dabrafenib and Trametinib in BRAF V600 Mutant Melanoma
NCT02915666Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of digoxin in melanoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Frequency of Dose Limiting Toxicities. Planned start Oct 2016; status: withdrawn.
02
Drugs
digoxin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02915666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915666.